Evotec
- Colin Lindley
Colin Lindley
Svp, Head Of Global API Development, Industrialisation And Business Services at Evotec
Colin Lindley currently serves as the Senior Vice President and Head of Global API Development, Industrialisation and Business Services at Evotec, a position held since July 2022. With extensive experience in the pharmaceutical industry, Colin's career includes significant roles at Aptuit from 2007 to October 2022, where responsibilities ranged from Vice President of API Chemistry to Senior Project Manager. Prior positions include managerial and project leadership roles at Evotec and Oxford Asymmetry, as well as a technical officer role at Knoll Pharma. Colin holds a Master of Business Administration from The Open University, a Level 5 Diploma in Management from the Chartered Management Institute, a PRINCE2 Practitioner certification, and a Bachelor of Science with Honours in Applied Chemistry from Nottingham Trent University.
Org chart
This person is not in the org chart
Teams
This person is not in any teams
Offices
This person is not in any offices
Evotec
4 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.
